Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: Follow-up of two cases

Onkologie

Volumn 32, Issue 11, 2009, Pages 674-677

  Levchenko, Evgeny V ^a   Moiseyenko, Vladimir M ^a   Matsko, Dmitry E ^a   Iyevleva, Aglaya G ^a   Ivantsov, Alexandr O ^a   Yargnian, Stepan M ^a   Anisimov, Valentin V ^a   Semionov, Igor I ^a   Imyanitov, Evgeny N ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

EGFR; Gefitinib; Lung cancer; Mutation; Neoadjuvant therapy

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; KI 67 ANTIGEN;

ADJUVANT THERAPY; ADRENAL METASTASIS; ADRENALECTOMY; ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; DYSTROPHY; FEMALE; FEVER; FOLLOW UP; GENE DELETION; GENE MUTATION; HEMOPTYSIS; HUMAN; INFLAMMATION; LOCAL METASTASIS; LUNG ADENOCARCINOMA; LUNG LOBE; LUNG LOBECTOMY; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPHOCYTIC INFILTRATION; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; RASH; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 70449378197     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000242220     Document Type: Article

References (15)

1. Loriot Y, Soria JC, Le Chevalier T: Expanding role of chemotherapy in lung cancer. Ann Oncol 2006;17(suppl 10):x101-x107. (Pubitemid 44541996)
2. Chang CH, Chen KY, Young-Xu Y, Kurth T, John Orav E, Yang PC, Arnold Chan K: The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung Cancer 2008;62:242-252.
3. Costa DB, Kobayashi S, Tenen DG, Huberman MS: Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007;58:95-103.
4. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
5. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC: Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-smallcell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753.
6. Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, Nakamura T, Miyake T, Ichinose Y: Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 2005;47:85-91. (Pubitemid 39643245)
7. Govindan R, Behnken D, Read W, McLeod H: Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. Ann Oncol 2003;14:1330-1331.
8. Takamochi K, Suzuki K, Sugimura H, Funai K, Mori H, Bashar AH, Kazui T: Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 2007;58:149-155.
9. Kappers I, Klomp HM, Burgers JA, Van Zandwijk N, Haas RL, van Pel R: Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol 2008;26:4205-4207.
10. Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, Jiang H, Watkins C, Armour A, Fukuoka M: Phase III, randomised, openlabel, first-line study of gefitinib (G) vs. carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small cell lung cancer (NSCLC) (IPASS). Ann Oncol 2008;19(suppl 8):viii1.
11. Sirera R, Catot S, Gonzalez-Larriba GL, Bover I, Alonso G, Valdivia J, Ibeas R, Lianes P, Martnez del Prado P, Rosell R: Customizing erlotinib in metastatic non-small sell lung cancer (NSCLC) patients (P) harboring EGFR mutations. Ann Oncol 2008;19(suppl 8):viii90.
12. Altorki N, Heymach J, Guarino M, Lee P, Felip E, Bauer T, Swann S, Roychowdhury D, Ottesen LH, Yankelevitz D: Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): a proof-ofconcept study. Ann Oncol 2008;19(suppl 8):viii89.
13. Tsuboi M, Kato H, Nagai K, Tsuchiya R, Wada H, Tada H, Ichinose Y, Fukuoka M, Jiang H: Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs 2005;16:1123-1128.
14. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-2246.
15. Lee KH, Han SW, Hwang PG, Oh DY, Kim DW, Chung DH, Im SA, Kim TY, Heo DS, Bang YJ: Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-smallcell lung cancer. Jpn J Clin Oncol 2006;36:344-350.